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The BRCA1 suppressor hypothesis:
An explanation for the tissue-specific
tumor development in BRCA1 patients
The tumor suppressor gene BRCA1 is required for the cellular
response to DNA damage and homologous recombination,
although the exact function it plays in these processes is
unclear (Moynahan et al., 1999; Scully and Livingston, 2000).
Consistent with the idea that BRCA1 plays a central house-
keeping role within cells, mice lacking BRCA1 die very early in
embryogenesis (E7.5 or earlier) due to extreme genomic insta-
bility and activation of the p53/p21 pathway (Gowen et al., 1996;
Hakem et al., 1996; Ludwig et al., 1997). Despite its apparent
central role in double-strand break repair, loss of BRCA1 func-
tion appears to affect only a very specific and small subset of
tissues in humans. Although a slight increase in predisposition
of other cancer types may exist in patients carrying a germline
mutation in the BRCA1 gene, a dramatic increase in predisposi-
tion is observed only for cancer of the breast and ovary in these
individuals (reviewed in Welcsh et al., 1998; Scully and
Livingston, 2000; Rosen et al., 2001). Most mutations in BRCA1
thus far represent single base pair deletions, insertions or large
genomic rearrangements likely causing a complete loss of func-
tion of BRCA1 due to the resulting frameshifts (Neuhausen and
Ostrander, 1997; Blackwood and Weber, 1998), excluding the
possibility that these BRCA1 mutations are weak hypomorphic
alleles.The phenotypes associated with these truncations are in
fact expected to be at least as deleterious as the BRCA1 muta-
tions made thus far in mice.
Why BRCA1 loss is not observed in sporadic breast and
ovarian cancer
The role of BRCA1 in breast cancer appears to be limited to
familial cases. The absence of BRCA1 mutations in sporadic
breast and ovarian tumors has been treated as a surprising
aspect of BRCA1 biology. However, given the properties of
familial BRCA1 disease, homozygous mutations in BRCA1 are
actually expected to be relatively rare in sporadic tumors. The
reasoning for this is as follows: women who inherit a mutant
allele of BRCA1 typically develop unilateral breast cancer with a
mean age of incidence of 50–70 years, depending on the study.
The overall penetrance of cancer in individuals inheriting one
mutant BRCA1 allele is 85% for breast cancer and 65% for
ovarian cancer during their lives (Easton et al., 1995). For a spo-
radic tumor to evolve from a BRCA1+/+ individual, the tumor
would first have to lose one BRCA1 allele spontaneously to
become BRCA1+/−, at which point those cells would have
approximately the same probability of becoming a tumor as
equivalent cells from BRCA1 heterozygous patients. Thus,
spontaneous tumors due to BRCA1 require an additional hit rel-
ative to those derived from BRCA1 heterozygotes and are cor-
respondingly less frequent.
The frequency of tumor occurrence of the BRCA1−/− geno-
type arising spontaneously from BRCA1+/+ individuals is, at
least to some extent, the frequency of conversion from
BRCA1+/+ to BRCA1+/− for an individual cell, i.e., the additional
hit, multiplied by the frequency of tumorigenisis in BRCA1+/−
patients (0.85 for breast tumors). An exact prediction of the
expected percentage of sporadic cases of BRCA1−/− tumors of
the breast and ovary is difficult to calculate for several reasons.
The spontaneous rate of forward mutagenesis, generally
thought to be between 1 in 10−6 to 1 in 10−7 mutations/genera-
tion for normal cells, is affected by the presence or absence of
prior genetic instability mutations. Furthermore, loss of het-
erozygozity of BRCA1 may only cause tumor formation effi-
ciently when it occurs during a certain developmental window.
The timing of occurrence of LOH is necessarily delayed for
spontaneous versus familial disease by the requirement for a
prior mutation to occur (BRCA1+/+ to BRCA1+/−). The frequency
with which a spontaneous BRCA1−/− tumor is observed among
breast cancer samples also depends on the number and fre-
quency of mutations other than BRCA1 that cause breast can-
cer.The more different types of genetic alterations cause breast
cancer and the more frequently such mutations occur, the less
frequent a tumor due to any one particular cause will be detect-
ed. The fact that 12% of women develop breast cancer in their
lifetime, a high number, means that a relatively large number of
tumors would have to be screened to identify the rare tumors
due to spontaneous BRCA1 loss.
Given the penetrance and relatively late onset of tumorigen-
esis in BRCA1 heterozygotes, spontaneous BRCA1−/− tumors
are expected to be relatively rare. This line of reasoning pro-
vides a general prediction for the relationship between inherited
and sporadic tumor suppressors: if the cancers caused by famil-
ial tumor suppressors occur early in the life of an individual who
inherits a mutant allele and with high penetrance, mutations
should also be observed in sporadic cancers; if the familial-
inherited cancers arise later in life and with relatively low pene-
trance, the sporadic forms are predicted to occur only rarely
because they require an additional hit.
Tissue specificity of tumorigenesis in BRCA1
heterozygous individuals
Why mutations in a generic DNA repair gene should show such
striking tissue specificity has been a source of much specula-
tion (reviewed in Welcsh et al., 1998; Scully and Livingston,
2000; Rosen et al., 2001). The concept of “redundancy” has
been put forth as one explanation of this phenomenon. It has
been proposed that most tissues have alternative ways of per-
forming BRCA1’s tumor suppressing functions. Therefore, loss
of BRCA1 in tissues with backup mechanisms has less of an
effect than loss in the tissues such as breast and ovary without
backup mechanisms. The embryonic defects observed in
knockout mice described below argue against a general redun-
dancy. Another plausible explanation involves the high prolifera-
tive activity in ovary and breast tissues. Cell proliferation in the
absence of BRCA1 may lead to a higher mutation rate, thereby
increasing the risk of acquiring a cancer-causing mutation.
However, other tissues such as the colon also have high prolif-
eration rates but do not show this high incidence of tumor for-
mation in affected individuals. BRCA1 has been implicated in
the regulation of transcription, and it is possible that it may reg-
ulate certain genes expressed only in the breast and ovaries.
The altered expression of these transcripts would lead to an
increase in neoplastic transformation through an as yet unde-
fined mechanism (Welcsh et al., 1998). Alternatively, ovary- and
breast-specific BRCA1 cofactors could cause transformation in
the absence of BRCA1. Finally, at least one report has suggest-
ed that BRCA1 plays an inhibitory role in estrogen receptor
(ER) signaling that could help explain the tissue specificity (Fan
et al., 2001). A fact relevant to this explanation is that most
BRCA1−/− tumors lack ER expression. It is currently unclear if
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BRCA1−/− tumors arose from cells that never expressed ER or
that lost ER expression during tumorigenesis. If these tumors
never expressed ER, however, it would call this potential expla-
nation into question.
The BRCA1 suppressor hypothesis
We would like to propose a new model for the tissue specificity
of tumor formation in BRCA1 patients that relies on the essen-
tial nature of BRCA1 (Figure 1). We propose that because
BRCA1 is an essential gene, the loss of BRCA1 leads to cell
death or a severe decrease in proliferation in tissues other than
the breast and ovary, thus reducing the likelihood that additional
mutations will occur that allow tumor formation. Only in the
breast and ovaries are BRCA1−/− cells able to survive long
enough for secondary mutations to occur that support cell prolif-
eration. Thus, the reason why loss of BRCA1 causes tissue-
specific tumor formation is not because most tissues have
“redundant” ways of repairing DNA and/or promoting cell sur-
vival, but that only breast and ovary tissues are able to survive
for a prolonged period of time in the absence of BRCA1.
This hypothesized increased survival may be due to genetic
factors unique to these particular tissues. Such genetic factors
might include the presence of additional DNA repair capacities
in these cells or expression of BRCA1-related proteins capable
of compensating for loss of certain BRCA1 functions. Other
genetic factors could result in a reduced propensity to undergo
DNA damage-induced cell death due to expression of higher
levels of antiapoptotic genes.
It is also possible that it is the physiological environment in
these tissues that promotes survival in the absence of
BRCA1. For example, the presence of survival factors in the
form of hormones may have a protective effect on individual
cells, allowing BRCA1−/− cells to survive and proliferate for a
prolonged period of time. Both the breast and ovaries are tar-
gets of estrogen and other hormones that have been shown to
endow anti-apoptotic survival functions upon cells, sometimes
in a cell nonautonomous manner (Gompel et al., 2000;
Kousteni et al., 2001).
If the lethality caused by the loss of both BRCA1 alleles is
suppressed even temporarily, further proliferation and sur-
vival-promoting mutations would accumu-
late due to the extreme genomic instabili-
ty caused by loss of BRCA1 function
(Figure 1). Once cells have acquired addi-
tional survival-promoting genetic changes
(suppressor mutations), they will rapidly
evolve further to form a tumor. The acqui-
sition of suppressor mutations that allow
these cells to survive independent of the
protective environment of the breast may
be a key step in their ability to ultimately
undergo metastasis.
The types of suppressor mutations that
will allow clone expansion are unknown, but clues can be
gleaned from experiments performed in mice. Mice homozy-
gous for the BRCA1 mutations die early in embryogenesis
(Gowen et al., 1996; Hakem et al., 1996; Ludwig et al., 1997).
However, when p21 or p53 are deleted in these mutant back-
grounds, embryos survive several days longer and even to birth
depending on the severity of the BRCA1 mutation examined
(Ludwig et al., 1997; Hakem et al., 1996; Cressman et al., 1999;
Xu et al., 2001). These experiments and others indicate that the
DNA damage response pathway is activated in the absence of
BRCA1. Therefore, mutations in the DNA damage response
pathway might be expected to suppress BRCA1 loss-of-func-
tion-associated cell lethality in non-breast and -ovary tissues
and contribute to tumorigenesis.
Predictions from this hypothesis
There are a few key predictions resulting from this hypothesis.
(1) Weaker alleles of BRCA1 may be expected to show cancer
predisposition in other tissues. Hypomorphic nonlethal alleles of
BRCA1 could survive in a homozygous state in tissues that do
not have the protective environment of the breast and ovaries.
The reduced genomic instability of these partial loss-of-function
alleles might be offset by the greater number of cells in the body
in which homozygous mutations can survive. A recent report
lends support for this hypothesis. Mice homozygous for a hypo-
morphic truncated BRCA1 allele (BRCA1tr) are viable and show
a strikingly broad tumor spectrum (Ludwig et al., 2001) includ-
ing lymphomas, sarcomas, and adenomas/carcinomas of the
breast, lung, and liver. Since we do not know the tumor spec-
trum of more deleterious BRCA1 alleles in mice, we cannot
determine if this hypomorphic allele extends the tumor spec-
trum, but it is consistent with the prediction put forth by our
hypothesis. (2) Promoting survival of BRCA1−/− cells in tissues
other than the breast and ovary by inhibiting apoptosis might
lead to tumor formation in these tissues. As noted above, loss of
p53, which leads to the inactivation of some apoptotic path-
ways, allows BRCA1 null animals to survive longer. Mice
homozygous for the loss of exon 11, a hypomorphic allele of
BRCA1, die between days E12 and E18 of gestation. Loss of
only one allele of p53 suppresses this lethality (Xu et al., 2001),
Figure 1. A schematic representation of the
BRCA1 suppressor hypothesis as an explanation
for breast and ovarian tissue specificity of cancer
in BRCA1 heterozygous individuals
See text for explanation. LOH: loss of heterozygosi-
ty. Colored circles represent cells of particular
genotypes. Changes in circle color indicate a
change in genotype.
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but these mice also show an increase in tumor susceptibility in a
wider range of tissues (Xu et al., 2001). Similarly, loss of com-
ponents of the DNA damage checkpoint might suppress the
lethality of BRCA1−/− cells and expand the tumor spectrum in
BRCA1 mutant mice.
BRCA1 is an unusual tumor suppressor in that it is virtually
essential for cell viability due to its role in maintaining genomic
integrity. Other genes with these general properties are likely to
exist and give rise to a similar tissue distribution of tumorigene-
sis. In addition to BRCA2 whose mutation results in early
embryonic lethality in mice (Ludwig et al., 1997) and tissue-spe-
cific tumor occurrence in humans, there are other genes that
could be members of this class of tumor suppressors. RAD51,
which associates with BRCA1 and BRCA2, is one such candi-
date. RAD51, like BRCA1 and BRCA2, is required for embryon-
ic development. However, thus far, RAD51 has not been report-
ed to be mutated in familial breast cancer. Perhaps other com-
ponents of the homologous recombination repair pathway and
proteins known to associate with BRCA1, such as those in the
BASC complex (reviewed in Welcsh et al., 1998; Scully and
Livingston, 2000; Rosen et al., 2001), may also be members of
the BRCA1 class of tumor suppressors, assuming that it is this
aspect of BRCA1 function that is relevant for tumor prevention.
Other essential genes involved in genomic stability like ATR and
CHK1 may be members of the BRCA1 class of tumor suppres-
sors. However, unlike in the case of BRCA1 and BRCA2
mutants, the early embryonic lethality of these mutants is not
rescued by loss of p53 (Liu et al., 2000; Brown and Baltimore,
2000).This suggests that loss of ATR and CHK1 causes a more
severe defect in DNA metabolism and/or checkpoint function
than does loss of BRCA1. This more severe defect may not be
rescued by a survival-promoting genetic or physiological envi-
ronment. It is, however, tempting to speculate that hypomorphic
alleles of these genes would show breast and ovary specificity
for tumorigenesis.
In general, tissue-specific tumor suppressors gain their
specificity by exploiting unique properties of their target tissues.
Rb may exploit the dependency of retinal tissues for differ-
entiation on the Rb pathway. Mutations in ATM, which is specifi-
cally required for the response to double-strand breaks, shows
a high preponderance of leukemias and lymphomas, which are
derived from cell types that undergo double-strand breaks in the
course of developing their immune repertoire. We propose that
essential genes like BRCA1 and BRCA2 adhere to this general
paradigm and are likely to be exploiting a cell survival aspect of
the breast and ovaries to gain their tissue specificity.
Implications of the suppressor hypothesis for therapy
If this suppressor hypothesis is correct, identifying the genetic
and environmental factors that enhance survival of cells
homozygous for BRCA1 mutations will be a key aspect of the
successful prevention and treatment of this cancer. For exam-
ple, if estrogen is causing the supportive environment that
allows BRCA1 mutations to survive in the breast and ovary,
then antiestrogen therapies should decrease the incidence of
breast and ovarian cancers in patients carrying BRCA1 muta-
tions.This protective effect would be highest before a tumor has
occurred. Estrogen has been shown to induce expression of
other survival factors such as Igf1 and Wnt (Rutanen, 1998;
Sassoon, 1999). It is possible that interfering with these proteins
may provide a means of prevention that has fewer deleterious
side effects than antiestrogen therapies. It should be noted that,
although most BRCA1−/− tumors lack ER, the fact that estrogen
can signal through these paracrine mechanisms would still
allow estrogen to affect cells lacking the ER. A critical point with
respect to possible therapies is that we hypothesize that the
loss of the second BRCA1 allele should be an early event in the
initiation of breast cancer, well before the earliest onset of can-
cer in these patients. Therefore, any preventative therapies
aimed at preventing the survival of BRCA1−/− cells would have to
begin relatively early in life after the proposed protective envi-
ronment in the breast is established.
If cell models can be identified that allow BRCA1 null cells
to survive by the same mechanism as they do in the breast,
these lines can be used to search for drugs that specifically
inhibit their survival but do not affect BRCA1+/+ cells. These
drugs could open new avenues for preventative therapies and
may also have palliative effects on early tumors in situ which
may still benefit from the putative protective environment of the
breast and ovaries.
The authors would like to note that the ideas put forth in this
essay are purely speculative and are made for the sole purpose
of spurring on research into this important area of biology. This
essay was not meant to be a comprehensive review of the liter-
ature concerning BRCA1, and we apologize to our colleagues
whose work we were not able to cover due to space constraints.
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